Guangshengtang announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a holding subsidiary of the company's innovative drug, is carrying out a randomized, double-blind, placebo-controlled phase II clinical trial of the GST-Peak-Triple full oral regimen to treat patients with chronic hepatitis B. Recently, participants in the first trial were successfully enrolled and administered.

Zhitongcaijing · 2d ago
Guangshengtang announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a holding subsidiary of the company's innovative drug, is carrying out a randomized, double-blind, placebo-controlled phase II clinical trial of the GST-Peak-Triple full oral regimen to treat patients with chronic hepatitis B. Recently, participants in the first trial were successfully enrolled and administered.